Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Bristol-Myers Squibb Company    BMY

BRISTOL-MYERS SQUIBB COMPANY (BMY)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets
The feature you requested does not exist. However, we suggest the following feature:

BMY The Law Offices of Vincent Wong Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Bristol-Myers Squibb Company

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/16/2018 | 10:58pm CET

The Law Offices of Vincent Wong notifies investors of an investigation concerning whether Bristol-Myers Squibb Company (“Bristol-Myers” or the “Company”) (NYSE: BMY) violated federal securities laws.

Click here to learn about the case: http://docs.wongesq.com/BMY-Info-Request-Form-1817. There is no cost or obligation to you.

On August 5, 2016, Bristol-Myers revealed that its CheckMate-026 trial exploring the use of Opdivo (nivolumab) as monotherapy failed to meet its primary endpoint of progression-free survival. Following this news, Bristol-Myers stock fell 16% to close at $63.28 per share on August 5, 2016. Then on October 9, 2016, Bristol-Myers revealed the final primary analysis of CheckMate-026, and that the overall Opdivo survival was only 14.4 months compared to chemotherapy's 13.2 months. Following this news, Bristol-Myers stock dropped over 10%, to close at $49.81 per share on October 10, 2016.

To learn more about the investigation of Bristol-Myers contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://docs.wongesq.com/BMY-Info-Request-Form-1817.

Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.


© Business Wire 2018
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BRISTOL-MYERS SQUIBB COMPA
02/16BMY The Law Offices of Vincent Wong Reminds Investors of an Investigation Inv..
BU
02/16BRISTOL-MYERS SQUIBB COMPANY : Pomerantz Law Firm Investigates Claims On Behalf..
AC
02/16BRISTOL MYERS SQUIBB : And Nektar To Collaborate On Immuno-Oncology Program
AQ
02/15Pivotal Phase 3 CheckMate -227 Study Demonstrates Superior Progression-Free S..
AQ
02/15BRISTOL MYERS SQUIBB : An Application for the Trademark "SLAMUNITI" Has Been Fil..
AQ
02/15BRISTOL MYERS SQUIBB : New Findings on Medicinal Chemistry Described by Investig..
AQ
02/15BRISTOL MYERS SQUIBB : New Deuterium Study Findings Have Been Reported by Invest..
AQ
02/15BRISTOL MYERS SQUIBB : Reports Summarize Capillary Electrophoresis Study Results..
AQ
02/15BRISTOL MYERS SQUIBB : Details Findings in Science (Chromatoprobe as a sample-sp..
AQ
02/15BRISTOL MYERS SQUIBB : New Drug Development Findings from Bristol-Myers Squibb O..
AQ
More news
News from SeekingAlpha
02/16Celgene's Otezla-Colitis Story; Implications For Other Biotechs 
02/16Bristol-Myers Squibb Looks For Growth Of Opdivo Beyond Development As A Singl.. 
02/15NETKAR : About The Bristol Myers Deal 
02/15Biotech Forum Daily Digest For February 15th 
02/15YOUR DAILY PHARMA SCOOP : Achaogen Update, Catabasis' Positive Results, Bristol-.. 
Financials ($)
Sales 2018 21 709 M
EBIT 2018 5 672 M
Net income 2018 5 211 M
Finance 2018 852 M
Yield 2018 2,37%
P/E ratio 2018 22,71
P/E ratio 2019 19,26
EV / Sales 2018 5,16x
EV / Sales 2019 4,64x
Capitalization 113 B
Chart BRISTOL-MYERS SQUIBB COMPA
Duration : Period :
Bristol-Myers Squibb Compa Technical Analysis Chart | BMY | US1101221083 | 4-Traders
Technical analysis trends BRISTOL-MYERS SQUIBB COMPA
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 64,9 $
Spread / Average Target -6,0%
EPS Revisions
Managers
NameTitle
Giovanni Caforio Chairman & Chief Executive Officer
Charles A. Bancroft CFO, EVP & Head-Global Business Operations
Paul von Autenried Chief Information Officer & Senior Vice President
Thomas James Lynch Chief Scientific Officer & Executive VP
Vicki L. Sato Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
BRISTOL-MYERS SQUIBB COMPANY6.64%112 900
JOHNSON & JOHNSON-7.19%352 552
NOVARTIS-3.37%224 301
PFIZER-2.84%212 857
ROCHE HOLDING LTD.-9.37%210 327
MERCK AND COMPANY-0.50%149 572